JOHCM Private Equity acquires Celsis International

JOHCM Private Equity is pleased to announce the completion of its acquisition of Celsis International plc for £51 million in a public-to-private transaction. This is the first investment in the new fund, Trident Private Equity Fund III. Celsis, headquartered in Cambridge UK, has been delisted from the London Stock Exchange.

Celsis is a leading provider of innovative life-science products and laboratory services. It delivers substantial time and cost savings to major pharmaceutical and consumer product companies through ensuring product quality and safety for consumers. Its clients include many of the top 25 pharma companies and Fortune 50 consumer product companies. The company employs 230 people.

Celsis has three divisions: Celsis Rapid Detection, a world leader in rapid microbial testing of liquids for industry; Celsis Analytical Services, which provides cost effective analytical laboratory testing services to pharmaceutical and consumer product manufacturers; and Celsis In-Vitro Technologies, a pioneer and leader of in-vitro ADME-Tox products used in drug discovery and development.

Commenting on the acquisition, Jeremy Brade, senior partner at JOHCM Private Equity and a director of Celsis, said:

“We are delighted to add Celsis to our investment portfolio. We believe it is a market-leading company with substantial opportunity to achieve further growth and build value. We look forward to working with the excellent management team to optimise the success of the company.”